Peregrine Pharma rallies on Fast Track designation for bavituximab

Peregrine Pharmaceuticals (PPHM) soars 33% premarket.

The company has landed Fast Track designation for bavituximab in NSCLC.

Pivotal trial (SUNRISE) is underway. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs